Search

The article discusses the role of the HNF4-TET2-FBP1 axis in regulating gluconeogenesis and its implications for type 2 diabetes (T2D). The study reveals that TET2 plays a crucial role in controlling glucose production, with implications for T2D pathology. Additionally, the research suggests that metformin treatment may impact this axis, offering potential therapeutic targets for T2D treatment. The preprint has not yet undergone peer review, and more information can be found on biorxiv.org. [Extracted from the article]

A study conducted at Xuzhou Medical University in the People's Republic of China focused on the renoprotective effects of dulaglutide, a GLP-1 agonist, in patients with type 2 diabetes and diabetic kidney disease. The research found that dulaglutide led to significant reductions in urinary albumin and modulation of EMT-related proteins, potentially improving kidney function in these patients. The study was funded by various organizations and concluded that dulaglutide could be beneficial for individuals with type 2 diabetes and DKD. [Extracted from the article]

A recent study from the University of New South Wales in Sydney, Australia, explores the use of Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs) in both younger and older populations with obesity and Type 2 diabetes. The research highlights the potential benefits of GLP1BTs in managing weight loss and improving health outcomes in these groups. The study emphasizes the need for further research and data to better understand the effectiveness and safety of GLP1BTs in diverse age groups. [Extracted from the article]

Researchers at the University of South China conducted a study on the traditional Chinese herbal prescription Jiao-tai-wan (JTW) and its therapeutic effects on type 2 diabetes mellitus (T2DM). Through network pharmacology analysis, they identified active compounds and mechanisms of JTW in treating T2DM via the SRC/PI3K/AKT signaling pathway. The study found that JTW may alleviate glucose, insulin resistance, and lipid metabolism disorders, providing insights into potential active compounds and essential targets for treating T2DM. The research was peer-reviewed and published in the Journal of Ethnopharmacology. [Extracted from the article]

A new study discusses the development of a novel peripherally acting alpha2A-adrenergic receptor antagonist, CDS479-2, as a potential treatment for type 2 diabetes. This derivative of yohimbine shows similar antagonist activity to yohimbine but with limited access to the brain, reducing unwanted central side effects. In animal models, CDS479-2 demonstrated the ability to lower blood glucose levels, improve glucose tolerance, sustain normoglycemia, and increase insulin-producing beta cells, suggesting a promising direction for type 2 diabetes treatment. The study also highlights the potential for optimizing drugs with both peripheral and central targets in the future. [Extracted from the article]

A recent study conducted at the University Clinical Hospital of Santiago de Compostela in Spain examined the use of the CNIC-polypill in patients with type 2 diabetes and cardiovascular disease. The CNIC-polypill, which includes acetylsalicylic acid, ramipril, and atorvastatin, was found to be more effective in reducing the risk of recurrent major adverse cardiovascular events compared to other therapeutic strategies. Patients treated with the CNIC-polypill also showed better control of risk factors, medication persistence, and lower healthcare costs. The research concluded that the CNIC-polypill offers improved clinical outcomes and economic efficiency for patients with cardiovascular disease, particularly those with type 2 diabetes. [Extracted from the article]

A study conducted at Akdeniz University in Antalya, Turkey, compared the clinical outcomes of dapagliflozin and empagliflozin in patients with type 2 diabetes mellitus. The study found that both drugs led to a significant decrease in glycosylated hemoglobin levels and urine albumin-to-creatinine ratio. The research suggests that dapagliflozin and empagliflozin are effective choices for renoprotection in diabetic patients, regardless of the use of a renin-angiotensin-aldosterone system blocker. Further comparative trials are recommended to explore potential differences in the time to addition of new anti-diabetic agents between the two drugs. [Extracted from the article]

The article discusses the heterogeneity of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects about 70% of obese individuals but can also be found in lean people. The authors highlight the varied responses to pharmacological treatments for MASLD and emphasize the importance of understanding the different pathomechanisms to enable personalized risk prognosis and treatment. MASLD is a global epidemic with significant health risks, including progression to cirrhosis, type 2 diabetes, cardiovascular disease, and extrahepatic cancers. Researchers aim to develop tailored therapies based on the diverse aspects of the disease to address this growing health concern. [Extracted from the article]

A patent application by Carmot Therapeutics Inc. aims to address the global obesity epidemic and its associated complications, such as cardiovascular disease and type 2 diabetes mellitus. The inventors propose a method of weight management and improving glycemic control in overweight or obese adults, involving the administration of a compound via subcutaneous injection. The therapy seeks to reduce visceral adiposity and HbA1c levels, offering a potential solution for chronic weight management and glycemic control in individuals with or without weight-related comorbidities like type 2 diabetes mellitus. [Extracted from the article]

The article discusses a study on the composition of endocrine cells in human islets and its impact on insulin secretion, genetic risk for type 2 diabetes, and personalized medicine. The research, based on data from organ donors without diabetes, reveals significant heterogeneity in islet cell composition related to various factors such as hormone secretory traits, sex, race, ancestry, and genetic risk for diabetes. The findings suggest implications for understanding diabetes heterogeneity, islet dysfunction, and potential strategies for personalized medicine and beta cell replacement therapy. [Extracted from the article]

The article discusses a study on a dual enzyme inhibition strategy for Type 2 Diabetes, targeting LDH-A and alpha-amylase with flavonoid-acarbose combinations. Diabetes mellitus affects over 100 million people globally and increases the risk of severe complications. The study investigates the potential of flavonoids in green and black tea to inhibit these enzymes, with Quercetin showing potent anti-LDH-A activity. This preprint has not been peer-reviewed and provides valuable insights into potential treatments for Type 2 Diabetes. [Extracted from the article]

A study conducted at Shanghai Jiao Tong University focused on the impact of GLP-1 receptor agonist therapy on lipid profiles in patients with type 2 diabetes. The research found that patients with early-stage type 2 diabetes displayed significant lipidomic abnormalities that were partially improved after treatment with dulaglutide and liraglutide. The study highlighted specific lipid species that were altered in response to the treatments, indicating potential benefits for managing type 2 diabetes. [Extracted from the article]

Researchers at the Instituto Nacional de Medicina Genomica in Mexico City conducted a study on Type 2 Diabetes (T2D) and the pharmacogenomics of metformin, a common treatment for T2D. The study identified genetic variants in SLC transporter genes that affect metformin pharmacokinetics and response in Mexican patients. The findings suggest the potential for precision medicine and personalized treatment options, particularly for populations with a high susceptibility to metabolic diseases like Latin Americans. The research was funded by Conahcyt and published in Pharmaceuticals. [Extracted from the article]

A patent application by inventor Ardian Latifi for a garment designed to support the gastrointestinal tract and improve posture has been made available online. The garment aims to address issues related to gastrointestinal diseases, metabolic syndrome, and obesity by lifting and compressing the lower GI tract while supporting the back. The invention is intended to enhance GI function, promote weight reduction, and treat various physiological and morphological abnormalities associated with GI health. The garment is designed to be worn for extended periods to achieve the desired therapeutic effects. [Extracted from the article]

Researchers from the Medical University of Silesia in Poland have conducted a study on the relationship between obesity and type 2 diabetes mellitus (T2DM). The study highlights the significance of paracrine factors such as growth differentiation factor 15 (GDF-15), mesencephalic astrocyte-derived neurotrophic factor (MANF), and fetuin-A in the diagnosis and treatment of T2DM and obesity. The research emphasizes the potential prognostic, diagnostic, and therapeutic benefits of these factors in managing T2DM and its associated complications. The study suggests that these paracrine factors could play a crucial role in predicting the development and progression of T2DM, offering new insights into the management of this prevalent metabolic disease. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential of a novel Cdk5 inhibitor in treating type 2 diabetes (T2D) and cognitive decline. T2D is often associated with cognitive decline and is linked to Alzheimer's disease. The researchers identified two brain-penetrant Cdk5 inhibitors, BLINK11 and BLINK15, which showed promise in improving T2D pathogenesis, including blood glucose, obesity, and cognitive impairment. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A study conducted by researchers at Imperial College London analyzed data from the May Measurement Month (MMM) campaign between 2017 and 2019 to evaluate hypertension control and the frequency of comorbidities among adults aged 18 years and older. The study found that 34.2% of participants had hypertension, and 12.1% had at least one other chronic condition. Among those with hypertension, 58.9% were on medication, and 43.1% of those on medication had their hypertension controlled. The study also revealed that individuals without comorbidities had poorer hypertension management. These findings highlight the high prevalence of comorbidities in individuals with hypertension and the need for improved management strategies. [Extracted from the article]

A recent study examined the genetic factors that influence weight loss from GLP1-RA therapy and bariatric surgery. The study included 10,960 individuals from nine multi-ancestry biobank studies in six countries. The results showed that genetic factors related to body weight and type 2 diabetes did not have a significant impact on the effectiveness of GLP1-RA therapy. However, a higher polygenic score for BMI was associated with lower weight loss after bariatric surgery. The study also found that both treatments were effective across different ancestral groups. It is important to note that this study has not yet undergone peer review. [Extracted from the article]

A research report from Yale University discusses the importance of glucose variability (GV) in individuals with type 2 diabetes. The study aims to identify risk factors associated with high GV, predict high GV using intra-person data, and examine the relationship between emotional well-being and GV. The research will recruit 200 adults with type 2 diabetes and use continuous glucose monitoring, actigraphy, and self-report tools to collect data on glucose levels, lifestyle factors, and emotional well-being. The findings will help identify high-risk groups and inform personalized interventions to improve diabetes outcomes. [Extracted from the article]

A recent report from the University of Washington discusses the use of glucagon-like peptide-1 receptor agonist (GLP-1RA) medications in individuals with type 1 and type 2 diabetes. These medications have been shown to effectively control glucose levels and reduce various complications. However, they can also increase the risk of hypoglycemia, particularly in patients with type 1 diabetes. The report reviews the effects of GLP-1RA formulations on hypoglycemia development and suggests strategies for safely initiating GLP-1RA therapy. This research has been peer-reviewed and provides valuable insights for individuals with insulin-treated diabetes. [Extracted from the article]

A recent study conducted in Karachi, Pakistan examined the prevalence of non-alcoholic fatty liver disease (NAFLD) and the effectiveness of oral hypoglycemic drugs and lifestyle modifications in reducing fatty liver changes and liver enzymes in patients with type 2 diabetes mellitus. The study involved 200 patients, with 154 (77%) having NAFLD with type 2 diabetes and 46 (23%) having only fatty liver changes. The participants were prescribed different combinations of oral hypoglycemic agents and were advised to make lifestyle modifications. The combination of empagliflozin + metformin, along with lifestyle modifications, was found to be highly effective in reducing fatty changes and liver enzyme levels. [Extracted from the article]

A recent study conducted at Taipei Veterans General Hospital in Taiwan aimed to evaluate the effectiveness of insulin treatment compared to oral anti-diabetic drugs (OAD) for patients newly diagnosed with type 2 diabetes with moderate hyperglycemia. The study randomized 50 patients to receive insulin, metformin, or sitagliptin treatment. After a 6-month course of treatment, the researchers found that insulin therapy did not provide any significant benefits in terms of insulin sensitivity or insulin secretion. The study concluded that basal insulin therapy may not be advantageous for patients with newly diagnosed diabetes and moderate hyperglycemia. [Extracted from the article]

A recent report from Stanford University Medical Center discusses the findings of a study on the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and metformin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (diabetic MASLD). The study aimed to evaluate the long-term effects of these medications on liver and non-liver complications. The results showed that SGLT-2i users had a significantly lower risk of liver complications, cardiovascular disease, chronic kidney disease, and non-liver cancer compared to users of other glucose-lowering drugs. The risk was further reduced when SGLT-2i was used in combination with metformin. This research provides valuable insights into potential pharmacological therapies for patients with type 2 diabetes and diabetic MASLD. [Extracted from the article]

A new report discusses research findings on type 2 diabetes, specifically focusing on a rare case of recurrent hyperinsulinemic hypoglycemia in a patient with diabetes. The report highlights the diagnostic challenges and management difficulties associated with this condition, as well as the novel association of antibody-negative Graves' disease with insulinoma and nesidioblastosis. The researchers also discuss the use of acarbose and uncooked cornstarch to maintain euglycemia in this patient. For more information, readers can refer to the full research article. [Extracted from the article]

A recent study conducted in Recife, Brazil suggests that metabolic disorders such as diabetes and obesity may be significant risk factors for psychiatric disorders. The researchers propose that drugs originally developed to treat antidiabetic conditions could potentially be repurposed as novel antidepressant medications. The study focused on a mouse model of depression linked to type 2 diabetes induced by a high-fat diet, and found that the drug semaglutide effectively mitigated depressive and anxiety-like behaviors, improved cognitive function, and protected synaptic plasticity. The researchers concluded that semaglutide has the potential to be a therapeutic tool for depression and anxiety. [Extracted from the article]

Researchers from the Instituto Politecnico de Lisboa conducted a study to assess medication adherence in patients with Type 2 Diabetes Mellitus and Arterial Hypertension. The study found that while most patients initiated drug therapy after prescription, very few had a medication possession rate (MPR) high enough to be considered adherent. The implementation rate for antihypertensive therapy was higher than for oral antidiabetic therapy, indicating that medication adherence patterns are influenced by both the patient and the disease itself. This research provides valuable insights into medication adherence in chronic diseases and can inform healthcare professionals in improving patient outcomes. [Extracted from the article]

A recent study conducted by the University of Medicine and Pharmacy in Timisoara, Romania, explored the relationship between coffee consumption, a specific gene polymorphism (CYP1A2), and type 2 diabetes (T2DM) in a Romanian population. The study found that individuals with the AA genotype, or fast metabolizers, consumed the most coffee and had higher glucose and cholesterol levels. Additionally, there was a significant correlation between coffee intake and glucose levels in both the diabetic and control groups. The researchers concluded that caffeine levels, glucose, and cholesterol are interconnected and proportionally related, regardless of T2DM. [Extracted from the article]

A recent study aimed to understand the regulatory network of Type 2 diabetes (T2D) and identify potential drug targets and candidates. The researchers performed differential gene expression analysis on multiple T2D datasets and constructed protein-protein interaction networks to identify key hub genes. EGFR emerged as a consistently top-ranked hub gene, and the regulatory network included genes involved in processes such as apoptosis regulation and reactive oxygen species metabolism. The study also used virtual screening and molecular dynamics simulations to identify three compounds with strong binding affinities to EGFR, offering promising avenues for T2D treatment. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

The article discusses a clinical trial in Mexico City called the Prediabetes Care Program (PreCPro), which aims to address the issue of prediabetes, a precursor to type 2 diabetes, in Mexico. The program focuses on promoting weight reduction and reducing hyperglycemia through lifestyle changes such as healthy eating and physical activity. It targets patients with prediabetes who receive regular care in public primary care services in Mexico City. The trial will assess outcomes such as glycemic control, weight change, lipid control, blood pressure, and health-related quality of life. The program is based on national and international guidelines for diabetes prevention and is currently recruiting participants. [Extracted from the article]

A new study conducted by researchers at Independent University in Bangladesh has found that the ethanolic extract of Mangifera indica (EEMI) leaves may have potential benefits for individuals with type 2 diabetes. The study investigated the insulin-releasing and glucose-lowering effects of EEMI in rats with streptozotocin-induced type 2 diabetes. The researchers observed that EEMI increased insulin secretion, inhibited carbohydrate digestion and absorption, and improved various metabolic parameters in the rats. The study suggests that the naturally occurring phytoconstituents in EEMI could be used to develop enriched antidiabetic therapies. [Extracted from the article]

Researchers from Mawlana Bhashani Science and Technology University in Tangail, Bangladesh have conducted a study on the potential pathways and biomarkers of pancreatic cancer associated with lynch syndrome and type 2 diabetes. Using computational and systems biology approaches, the researchers identified common differentially expressed genes (DEGs) and potential target candidates. They also analyzed protein-protein interactions, gene ontology, and signaling pathway networks. The study sheds light on the genetic risk factors and potential therapeutic compounds for these diseases, providing a basis for further exploration and validation. [Extracted from the article]

Researchers from Hasanuddin University in Makassar, Indonesia have conducted a study on the potential use of marine algae-derived peptides (MAP) in managing Type 2 Diabetes (T2D). Through pharmacoinformatics and in vitro methods, the researchers identified and assessed the bioactivity, toxicity, and drug-likeness of various peptides. They found that the peptide FDGIP from Caulerpa lentillifera showed promising antidiabetic properties, with in vitro data confirming its activity. The researchers concluded that FDGIP could be used in food formulations to manage T2D. This study provides new insights into the potential of MAP as functional molecules for modulating T2D markers. [Extracted from the article]

A study conducted at Zhejiang University in Hangzhou, China, investigated the effects of combining Exenatide and Metformin on patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. The study included 128 patients who were randomly assigned to either Group A (receiving Metformin) or Group B (receiving Exenatide injection and Metformin). After 24 weeks of treatment, Group B showed lower levels of fasting blood glucose, postprandial glucose, triglycerides, total cholesterol, alanine aminotransferase, and aspartate aminotransferase compared to Group A. Additionally, Group B had lower counts of Escherichia coli and Enterococcus faecalis, and higher counts of Bifidobacteria and Lactobacillus. The researchers concluded that the combination of Exenatide and Metformin may have synergistic effects in improving metabolic and hepatic parameters, as well as regulating intestinal flora, providing a promising therapeutic option for these patients. [Extracted from the article]

A recent report discusses research on type 2 diabetes and its connection to Alzheimer's Disease (AD). The study explores the potential benefits of heat therapy in improving glycemic control and reducing inflammation. The pilot study involved 18 older individuals at risk for AD, who underwent four weeks of heat therapy. Preliminary data showed positive effects on body mass index, mean arterial pressure, cerebral perfusion, and self-reported sleep quality. Further studies are needed to fully understand the impact of heat therapy on glucose homeostasis and brain health. [Extracted from the article]

A recent study conducted by researchers at the National Autonomous University of Mexico (UNAM) aimed to characterize two rat models of diabetes: one induced by a high-fat diet combined with streptozotocin administration, and the other induced by a single dose of streptozotocin. The study found that the high-fat diet model exhibited stable hyperglycemia and insulin resistance, while the streptozotocin model showed a more moderate insulin response. Microarray experiments on liver tissue revealed differentially expressed genes between the two models, with pathways related to lipid biosynthesis and metabolism identified in the streptozotocin model, and pathways related to immunometabolism identified in the high-fat diet model. The researchers concluded that these models are reliable for studying type 1 and type 2 diabetes, respectively, and provide insight into liver gene expression and potential complications associated with impaired liver function. [Extracted from the article]

A recent study conducted at Haikou People's Hospital in China investigated the therapeutic effect of liraglutide on acute cerebral infarction (ACI) in patients with type 2 diabetes mellitus (T2DM). The study found that liraglutide combined with insulin glargine effectively controlled blood sugar, reduced insulin resistance, alleviated neurological damage, and improved clinical efficacy in T2DM patients with ACI. The study also observed that the levels of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were higher in the group treated with liraglutide compared to the control group. These findings suggest that liraglutide may have potential benefits for T2DM patients with ACI. [Extracted from the article]

A patent application has been made available online for methods of treating metabolic disorders using genetically engineered variants of a protein called FGF21. The application explains that these variants, such as V103, have shown positive effects in animal models of insulin resistant type 2 diabetes and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). The application suggests that these FGF21 variants could be used as a frontline therapy for metabolic disorders, including hypercholesterolemia, dyslipidemia, NAFLD, NASH, type 2 diabetes, and obesity. The treatment aims to reduce body weight, liver fat content, LDL-C, total-C, triglyceride, and Apo B levels, while increasing HDL-C levels and reducing cardiovascular risk. The protein variant can be administered subcutaneously at various doses and frequencies, and there is also the possibility of combining it with other therapeutically active agents. [Extracted from the article]

A study conducted at North China Electric Power University Hospital in Beijing, China investigated the efficacy of combining valsartan and amlodipine in the treatment of patients with type 2 diabetes mellitus (T2DM) and hypertension. The study analyzed the medical records of 110 patients and compared the therapeutic effect and incidence of adverse effects between a control group and a study group. The results showed that the combination of valsartan and amlodipine effectively treated T2DM co-morbid with hypertension, effectively controlled blood glucose levels and blood pressure, and had a relatively high level of safety. Further experiments are needed to confirm these findings. [Extracted from the article]

A recent study conducted by researchers at Kyorin University School of Medicine has found that the drug Imeglimin may help mitigate the accumulation of dysfunctional mitochondria in pancreatic b-cells, which can lead to impaired insulin secretion and type 2 diabetes. The study compared Imeglimin to the anti-diabetic drug metformin and insulin, and found that Imeglimin and insulin were effective in reducing reactive oxygen species and dysfunctional mitochondria, as well as restoring insulin secretion and reducing b-cell apoptosis in diabetic mice. These findings suggest that Imeglimin could potentially contribute to preserving b-cell function and glycemic control in type 2 diabetes. [Extracted from the article]

A recent report from McMaster University discusses the feasibility and acceptability of a co-designed virtual health coaching intervention called Technology-Enabled Collaborative Care for Type-2 Diabetes and Mental Health (TECC-D). The study found that the program was feasible and acceptable, indicating that virtual diabetes and mental health care could play a role in improving the quality of life for individuals with Type-2 diabetes and mental health concerns. The TECC-D model empowers individuals to take an active role in their care and is seen as a scalable solution. The research provides valuable insights into personalized medicine and the potential benefits of technology-enabled collaborative care. [Extracted from the article]

This patent application discusses the invention of nucleic acid molecules encoding FGF21 mutant polypeptides, which have potential applications in treating metabolic disorders such as diabetes and obesity. The application describes various amino acid substitutions in the FGF21 polypeptide sequence that can enhance its half-life and therapeutic efficacy. It also mentions the possibility of linking the polypeptides to polymers or fusing them with other amino acid sequences. Pharmaceutical compositions containing these FGF21 mutant polypeptides are proposed for the treatment of metabolic disorders. The application includes detailed information on the amino acid sequences, nucleic acid molecules, and vectors encoding the polypeptide. [Extracted from the article]

A recent study conducted in Holbaek, Denmark explored the use of personalized medicine and coordinated care in patients with both type 2 diabetes and cardiovascular disease. The study aimed to assess the feasibility and effectiveness of a multidisciplinary, shared care clinic for these patients. A total of 63 participants were enrolled in the clinic, with an average age of 69 years. The study will provide valuable information on the impact of this approach on cardiovascular risk factors and medication. This research is unique in its focus on patients with concomitant type 2 diabetes and cardiovascular disease. [Extracted from the article]

A Danish nationwide register study examined the discontinuation patterns of cardioprotective medication in elderly individuals with type 2 diabetes. The study found that the proportion of individuals on antihypertensive and antithrombotic medication at the time of death was high, with a slight increase over time. Discontinuations of medication occurred predominantly in the last year of life, but there was a more continuous discontinuation in the decade prior to death in recent calendar years. The study suggests an intensification of cardioprotective medication use among elderly individuals with type 2 diabetes, possibly due to increased focus on individualized treatment regimens. [Extracted from the article]

A study conducted by investigators at Wake Forest University compared the impact of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on health care costs for patients with type 2 diabetes. The study found that both procedures led to a decline in health care costs associated with type 2 diabetes, but RYGB was associated with a larger decrease in pharmacy costs and type 2 diabetes-specific office and laboratory costs. However, despite these reductions, RYGB did not result in an overall medical cost-benefit compared to SG in the first few years after surgery. The study was supported by the NIH National Institute of Diabetes & Digestive & Kidney Diseases. [Extracted from the article]

A recent study conducted by researchers from the Service of Endocrinology in Saint-Mande, France, highlights the importance of improving the care of elderly individuals living with type 2 diabetes. The study emphasizes the need for individualized treatment goals based on the patient's clinical presentation. The researchers also discuss the potential benefits and risks of new therapeutic classes of drugs for cardiovascular and renal protection. The management of elderly diabetic patients should strike a balance between avoiding excessive laxity and unreasonable activism to minimize the risk of hypoglycemia. This research has been peer-reviewed and provides valuable insights into the care of elderly individuals with type 2 diabetes. [Extracted from the article]

A recent study from the University of Surrey and the University Medical Centre Hamburg found that melatonin treatment does not affect insulin resistance or glucose tolerance in night shift workers, who are at a higher risk for Type 2 diabetes. However, melatonin treatment did significantly improve the sleep quality of these workers. The study involved 24 night shift workers and 12 non-shift workers, and after 12 weeks of melatonin treatment, there was no significant effect on serum glucose or insulin concentrations or blood pressure. The researchers concluded that while melatonin improves sleep quality, alternate methods are needed to improve insulin resistance and reduce the risk of type 2 diabetes. [Extracted from the article]

A study conducted by researchers from Osaka University has found that gargling with an antiseptic mouthwash can reduce the number of periodontitis-related bacteria in individuals with type 2 diabetes. The study involved 173 patients who gargled with water for the first six months and then switched to the mouthwash for the next six months. The researchers observed a reduction in bacterial species when patients used the mouthwash, particularly in younger patients who also experienced better blood-sugar control. This finding suggests that antiseptic mouthwash could be a simple and effective treatment for individuals with periodontitis-linked diseases such as diabetes, dementia, cardiovascular disease, and respiratory tract infections. [Extracted from the article]

A study conducted at Hainan Medical College in Haikou, China, investigated the efficacy of combining minocycline and periodontal basic treatment in patients with type 2 diabetes mellitus (T2DM) and chronic periodontitis (CP). The study involved 90 T2DM patients with CP who were randomly assigned to either a study group or a control group. The study group received minocycline in addition to routine hypoglycemic control and basic periodontal treatment, while the control group received only routine hypoglycemic control and basic periodontal treatment. The results showed that the combination of minocycline and periodontal basic treatment improved the efficacy in T2DM patients with CP and reduced the level of inflammatory factors. [Extracted from the article]